SK bioscience Co.,Ltd. (KRX:302440)

South Korea flag South Korea · Delayed Price · Currency is KRW
44,100
+800 (1.85%)
May 6, 2026, 3:30 PM KST
Market Cap3.46T +17.3%
Revenue (ttm)651.37B +143.5%
Net Income-57.42B
EPS-733.00
Shares Out78.46M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume309,866
Average Volume116,288
Open42,900
Previous Close43,300
Day's Range42,550 - 45,000
52-Week Range38,700 - 61,300
Beta0.93
RSI52.69
Earnings DateAug 12, 2026

About SK bioscience

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical tr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 917
Stock Exchange Korea Stock Exchange
Ticker Symbol 302440
Full Company Profile

Financial Performance

In 2025, SK bioscience's revenue was 651.37 billion, an increase of 143.46% compared to the previous year's 267.55 billion. Losses were -57.42 billion, 6.58% more than in 2024.

Financial Statements